Some drugs are going generic this year and next
August 3, 2012 By Alexia Elejalde-Ruiz in Medications
Dozens of brand-name prescription drugs are losing their patent protection, allowing generic versions to enter the market and consumers to save 30 to 80 percent on those medications, said David Belian, director of media relations for the Generic Pharmaceutical Association.
Generic forms of drugs have the same active ingredients as their brand-name counterparts but are significantly cheaper because they don't invest in clinical trials or advertising, Belian said.
About 80 percent of prescriptions are filled with generic drugs, and they have a good track record, said Howard Schiff, executive director of the Maryland Pharmacists Association. But some generic drugs may not work as well as the original brands, so before making the switch consider consulting your doctor who can write a prescription specifying brand-name or generic, Schiff said.
These are the prescription drugs that have been or are expected to be released as generics in 2012 and 2013, according to Medco Health Solutions, which manages pharmacy benefits for employer health plans.
2012: Symbyax (treatment-resistant depression); Geodon (schizophrenia, bipolar disorder); Lexapro (depression, anxiety); Seroquel (schizophrenia, bipolar disorder); Avandia (Type 2 diabetes); Avandamet (Type 2 diabetes); Avandaryl (Type 2 diabetes); Avapro (high blood pressure); Avalide (high blood pressure); Provigil (excessive sleepiness); Plavix (prevents blood clots); Viramune (HIV infection); Lescol/Lescol XL (high cholesterol); Tricor (high cholesterol); Clarinex/Clarinex D (allergy symptoms, hives); Singulair (asthma and allergy symptoms); Actos (Type 2 diabetes); Xopenex (asthma, COPD); Revatio (pulmonary arterial hypertension); Diovan/Diovan HCT (high blood pressure); Detrol (overactive bladder); Lidoderm (pain from post-herpetic neuralgia); Atacand/Atacand HCT (high blood pressure); Evoxac (Sjogren's syndrome); Maxalt/Maxalt MLT (migraines); Actoplus Met (Type 2 diabetes).
2013: Opana ER (pain); Zometa (bone complications from cancer); Valcyte (viral infections); Zomig (migraines); Fosamax Plus D (osteoporosis); Rilutek (amyotrophic lateral sclerosis); Temodar (glioblastoma multiforme); Cerezyme (Gaucher disease); Niaspan (high cholesterol); Advicor (high cholesterol); AcipHex (GERD); Vivelle-DOT (menopausal symptoms); Cymbalta (depression, anxiety, nerve/musculoskeletal pain, fibromyalgia).
(c)2012 Chicago Tribune
Distributed by MCT Information Services
-
Americans turn to generic medications in 2010: report
Apr 22, 2011 |
not rated yet |
0
-
Global spending on drugs to slow through 2016
Jul 12, 2012 |
not rated yet |
0
-
US prescription drug use fell in 2008, study says
May 13, 2009 |
not rated yet |
0
-
Drug prices to plummet in wave of expiring patents
Jul 25, 2011 |
not rated yet |
0
-
FDA approves first generic versions of Zyprexa
Oct 24, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Engineered cytomegalovirus protects monkeys from HIV equivalent
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
Driving and hands-free talking lead to spike in errors, study shows
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
Depression raises diabetics' risk of severe low blood sugar episodes
(Medical Xpress)—Patients with diabetes who are depressed are much more likely to develop episodes of dangerously low blood sugars, or hypoglycemia, than are those who are not depressed, a new study has ...
Aug 12, 2012
Rank: not rated yet